Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICI plus R-DA-EPOCH versus R-DA-EPOCH in untreated HIV-associated diffuse large B-cell lymphoma
ChiCTR2600132184Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tislelizumab, rituximab, etoposide, prednisone, vincristine and 2 more in diffuse large B-cell lymphoma (DLBCL) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoints: Tumor imaging assessment results, Adverse events and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
tislelizumabrituximabetoposideprednisonevincristine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2600132184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132184.